Alligator Bioscience AB (publ) reported earnings results for the third quarter and nine months ended September 30, 2023. For the third quarter, the company reported sales was SEK 19.41 million compared to SEK 5.11 million a year ago. Revenue was SEK 19.9 million compared to SEK 5.24 million a year ago. Net loss was SEK 52.5 million compared to SEK 51.37 million a year ago. Basic loss per share from continuing operations was SEK 0.08 compared to SEK 0.23 a year ago. Diluted loss per share from continuing operations was SEK 0.08 compared to SEK 0.23 a year ago.
For the nine months, sales was SEK 46.37 million compared to SEK 15.63 million a year ago. Revenue was SEK 49 million compared to SEK 16.23 million a year ago. Net loss was SEK 178.76 million compared to SEK 140.15 million a year ago. Basic loss per share from continuing operations was SEK 0.45 compared to SEK 0.64 a year ago. Diluted loss per share from continuing operations was SEK 0.45 compared to SEK 0.64 a year ago.